A treatment for major depression that rapidly resulted in full symptomatic remission for increased numbers of patients would be a significant clinical advance. Continuing impairment has been attributed not only to nonresponse, but also to improvement without full remission. Most previous research has assumed a several week lag before antidepressants work, attributable to mechanistic delays translating immediate drug actions into mood and behavioral effects. Additional delays in prescribing maximal dose and in ultimately prescribing effective treatment if initial therapy is ineffective also increase time to remission. Eliminating these delays would be a major public health boon. This two-site, randomized, double-blind study of 240 patients with DSM-IV Major Depressive Disorder will test whether combining escitalopram (ESC) and buproprion (BUP) accelerates response and increases the proportion in full remission. ESC + BUP (N=80) will be contrasted with ESC+ placebo (N=80), and separately with BUP+placebo (N=80). Six months follow-up will assess durability and costs. This study is based on both translational application of pre-clinical synergy between ESC and BUP, and on preliminary clinical data demonstrating rapid remission of major depression in 40 patients treated with ESC + BUP. In rat dorsal raphe, a marked increase in 5-HT neuronal firing was demonstrated to be superior to the mild synergistic effect. In humans, ESC + BUP resulted in both rapid remission (34% in the 1st two weeks) and increased final remission (62% at end of treatment). We conceptualize this study as the first in a series. If this study demonstrates an advantage for ESC + BUP, subsequent studies would replicate the rapid onset and greater overall effectiveness of ESC + BUP, document its long-term safety, durability and portability, investigate its utility relative to other dual therapies and the need for rapid dosing. Positive outcomes would argue for a major change in clinical practice with resultant marked decrease in depression's morbidity. Finally, this clinical finding could stimulate further preclinical work to develop better norepinephrine releasing agents or inhibitors of 5-HT1A autoreceptors and to investigate the interactive role of norepinephrine and 5-HT1A autoreceptors in the pathophysiology of Major Depressive Disorder and its treatment. ? ? ?
| Weissman, Myrna M; Wickramaratne, Priya; Pilowsky, Daniel J et al. (2015) Treatment of maternal depression in a medication clinical trial and its effect on children. Am J Psychiatry 172:450-9 |
| Bruder, Gerard E; Alvarenga, Jorge E; Alschuler, Daniel et al. (2014) Neurocognitive predictors of antidepressant clinical response. J Affect Disord 166:108-14 |
| Stewart, Jonathan W; McGrath, Patrick J; Blondeau, Claude et al. (2014) Combination antidepressant therapy for major depressive disorder: speed and probability of remission. J Psychiatr Res 52:7-14 |
| Gerra, Maria Lidia; Marchesi, Carlo; Amat, Jose A et al. (2014) Does negative affectivity predict differential response to an SSRI versus a non-SSRI antidepressant? J Clin Psychiatry 75:e939-44 |
| Pilowsky, Daniel J; Wickramaratne, Priya; Poh, Ernest et al. (2014) Psychopathology and functioning among children of treated depressed fathers and mothers. J Affect Disord 164:107-11 |
| Weissman, M M; Wickramaratne, P; Pilowsky, D J et al. (2014) The effects on children of depressed mothers' remission and relapse over 9 months. Psychol Med 44:2811-24 |
| Mullin, B C; Phillips, M L; Siegle, G J et al. (2013) Sleep deprivation amplifies striatal activation to monetary reward. Psychol Med 43:2215-25 |
| Batten, Lisa A; Hernandez, Mariely; Pilowsky, Daniel J et al. (2012) Children of treatment-seeking depressed mothers: a comparison with the sequenced treatment alternatives to relieve depression (STAR*D) child study. J Am Acad Child Adolesc Psychiatry 51:1185-96 |
